RESUMO
OBJECTIVE: The Vycross™ range of hyaluronic acid (HA) fillers supports a full-face approach to facial rejuvenation. It is important to understand how much filler can be safely injected and which products to use where, particularly for injectors who are new to this range. This study assessed whether Vycross fillers can be effectively and safely used in larger quantities and tracked real-world usage across facial zones. METHODS: This was a single-center, retrospective analysis set in normal clinical practice. The study included 66 consecutive adult female patients undergoing full-face rejuvenation with Vycross fillers within a single treatment plan guided by MD Codes. Filler usage and location were noted, and any adverse events were recorded. RESULTS: The mean age was 48.0 years, and median time from consultation to first filler usage was 18 days. Most patients (n=40; 60.6%) had only one filler session. Forty-seven patients (71.2%) also received botulinum toxin type A. In total, 309 filler syringes were used (mean: 4.7 per patient). Sixteen (5.2%), 181 (58.6%), and 112 (36.2%) syringes were used in the upper, mid and lower face, respectively. In the upper and midface, the majority was Voluma (15/16 and 120/181 syringes, respectively). In the lower face, filler use was split across Voluma, Volift and Volbella (41, 44 and 27 syringes, respectively). Five adverse events were reported at three weeks (swelling, n=2; asymmetry, n=2; lumps, n=1). All were easily resolved. No delayed events were reported. CONCLUSION: Substantial volumes of Vycross fillers can be effectively and safely used as part of a full-face approach to facial rejuvenation.
RESUMO
BACKGROUND: VYC-17.5L (17.5 mg/mL hyaluronic acid, 0.3% lidocaine) is a dermal filler intended for deep dermis injection for the treatment of skin depressions. OBJECTIVE: To evaluate 12-month effectiveness and safety of VYC-17.5L for the treatment of moderate/severe nasolabial folds (NLFs). METHODS: Subjects ≥18 years old with moderate/severe NLFs were recruited (N = 70). Injected volume was aimed at achieving optimum correction; top-up treatment was given at 2 weeks if needed. The primary endpoint was investigator-assessed change in NLF severity over 12 months using the validated photonumeric NLF Severity Scale. Secondary endpoints included investigator- and subject-assessed satisfaction and safety. Adverse events judged to be more severe or prolonged than routinely observed were recorded. RESULTS: Sixty-five subjects completed study requirements. Mean volume injected was 3.0 ± 1.0 mL for both NLFs combined. Significant improvement was maintained in investigator-assessed NLF severity at 12 months, and investigators and subjects reported high satisfaction with VYC-17.5L throughout the study. Two unexpected adverse events were reported: (1) redness, swelling, and decreased sensitivity (resolved after 4 days) and (2) swelling (resolved after 48 hours); neither event was serious or life threatening. CONCLUSION: VYC-17.5L is effective and well tolerated for the treatment of moderate to severe NLFs for 1 year.
